Myasthenia gravis (MG) is a serious, sometimes life threatening, debilitating condition associated with numerous symptoms including muscular weakness and fatigue. This study is to see how effective and safe rozanolixizumab is in adult patients experiencing moderate to severe symptoms of generalized myasthenia gravis (gMG).
The study consists of a Screening Period of up to 4 weeks, followed by a 6-week double-blind Treatment Period and an Observation Period of 8 weeks. During this 18 weeks period there will be 14 visits to the study clinic.
Adult patients with ALS that have been recently perscribed Edaravone may qualify to participate in this observational study. Blood and urine samples will be collected to evaluate the effects of Edaravone on ALS and the severity of ALS. During an estimated 12-month period, eligible participants will have approximately 15 clinic visits.
You are invited to volunteer for a research study if you have been diagnosed with Amyotrophic Lateral Sclerosis (ALS) within 2 years (24 Months) prior to screening.
This is a non interventional, longitudinal study in patients with ALS. There will be four (4) subject visits in this study: Baseline, month 6, month 12, and month 18. Subjects will have blood and cerebrospinal fluid (a clear fluid found in your brain and spine) collected, and be evaluated with assessment tools that focus on upper and lower motor skills and strength as well as cognitive function. Researchers will use these samples to study ALS, motor neuron disease and other medical conditions.